We are pleased to publish translations of the ICHD-3 in Bulgarian and Romanian - click here to visit the ICHD-3 section of the website.

ICHD-3 is also available in Brazilian Portuguese, Chinese, French, German, Japanese, Korean, Portuguese and Spanish.

Thanks to the dedicated work of members of the local Affiliate Member Societies who undertake this task on behalf of IHS.

Juniors Headache Science Excellence Tournament

Basic science: Zachariah Bertels - Differential effects of mu and delta opioid receptor agonists in models of chronic migraine-associated pain and aura

Clinical: Mohammad A.-M. Al-Karagholi - Opening of ATP sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine

Posters

Best poster (selected by the Juniors Group): James Mitchell - Detailed intra-cranial pressure monitoring in idiopathic intracranial hypertension probes diurnal and postural variability,

Best poster (selected by the Delegates): Hashmat Ghanizada - PACAP27 induces migraine-like attacks in migraine patients,

Other top posters

Raeburn Forbes - What proportion of anti-CGRP antibody therapy for migraine is contextual (placebo) effect?

Ditte Zhang - Blood glucose levels increase during spontaneous attacks of migraine with and without aura

Lawrence Robbins - CGRP monoclonal antibodies: first year results, controversies, and management Issues

The 2019 IHS Special Recognition Award, awarded to individuals who have contributed greatly to the Society, was awarded to Professor Fumihiko Sakai of Saitama International Headache Center, Japan.

Lars Edvinsson, IHS President, presented the award during the IHC 2019 Opening Ceremony, 5 September 2019.

Three IHS Short-stay scholarships were awarded to young clinicians / researchers to attend the International Headache Academy (iHEAD), IHC 2019 and then spend up to 6 weeks in Irish headahce centres, close to Dublin. The successful applicants were:

Gunjan Kumar, India. Host institution: Tallaght Hospital, Dublin – mentor: Sean O'Dowd

Agaath Hedina Manickam, India. Host institution: Beaumont Hospital, Dublin – mentor: Martin Ruttledge

Ana Podgorac, Serbia. Host institution: Mater Hospital, Dublin – mentor: Roisin Lonergan

Congratulations to all, and many thanks to the Irish centre mentors for welcoming them into their hospitals, and in particular to Martin Ruttledge, Co-Chair of IHC, who made the arrangements with the local centres.

Following the elections earlier this year, a new President-elect and three new Trustees joined the IHS Board of Trustees following the AGM on 6 September

President-elect: Cristina Tassorelli, Italy

Trustees: Fayyaz Ahmed, UK; Gianluca Coppola, Italy; Alexandra Sinclair, UK

Welcome to all

And many thanks to our retiring Trustees: David Dodick (Past-President), Anna Ambrosini, Rigmor Jensen, Gisela Terwindt (Elected Trustees), Mark Braschinsky, Chin-Sang Chung, Bronwyn Jenkins, Ingela Nilsson-Remahl (Co-opted Trustees)

Following the IHC in Dublin, several Committee Chairs have retired, and new and re-appointments made.

Classification - Jes Olesen retires after three decades as Chair during which three versions of the International Classification of Headache Disorders (ICHD) have been published. Many thanks to Jes for his tireless work on behalf of IHS and the Classification. Peter Goadsby has been appointed as his successor.

Clinical Trials – following her success in the IHS Presidential election, Cristina Tassorelli has stepped down as Chair. Gisela Terwindt will assume the role and continue the excellent work of the committee in developing and publishing international guidelines.

Education – Allan Purdy will continue as Chair of Education until 2021. As this is a key committee, with many activities, the Board agreed to appoint a Co-Chair to assist with the work. Henrik Schytz has been appointed and will work alongside Allan for the next 2 years.

Membership – Luiz Paolo de Queiroz has served 8 years as Chair and now retired. Thanks to Luiz Paolo for all his work for the committee. Anne Ducros has been appointed as Chair of this committee.

Re-appointments – each IHS Committee Chair serves a 4-year term, which is renewable for a further 4 years. Re-appointments at IHC 2021 are: Arne May – Cephalalgia Editorial; Anna Andreou – Electronic Media.

IHS is immensely grateful to all Committee and Special Interest Group Chairs for the dedication to the role and support of IHS.

Recent IHS Fellows, Doga Vurali, Inge Mulder, Olivier Brock and Kuan-Po Peng had the opportunity to present their Fellowship research at the IHC 2019 in Dublin on 6 September. Congratulations to all for a very successful session!

A slide kit to accompany the International Classification of Headache Disorders, 3rd edition (ICHD-3) is now uploaded and freely available to use.

To download please visit the IHCD/Guidelines section of the website

An article published recently in Cephalalgia Reports by Laura Schulte and colleagues notes that analysis of the 'Game of Thrones' series reveals that some characters survive head trauma. Read more here

On July 22, the World Federation of Neurology (WFN) is partnering with the International Headache Society (IHS) to support the highly anticipated 5^th Annual World Brain Day. This year, World Brain Day is dedicated to raising awareness for the most common brain disease in the world—migraine. Through this initiative, we are working alongside more than 120 organisations worldwide, to stop the stigma and build awareness around migraine.

Migraine is More than Just a Headache

Migraine affects one in seven people and, together with other headache disorders, is one of the leading causes of disability worldwide," explained Prof. Tissa Wijeratne, World Brain Day Chair.

"Lack of research support for and publications in the field of migraine from low to middle-income countries is disappointing and alarming. This is where nearly two-thirds of the world's population live. The situation in high-income countries is still in tremendous need of progress."

Despite its pervasive impact, migraine continues to be vastly under-recognised, underdiagnosed and under-treated. Due to a lack of education in headache medicine, it's not uncommon for health care providers to lack the tools necessary to diagnose and effectively treat patients. As a result, the majority of sufferers are not receiving the help they need.

"Migraine receives less research funding than all of the world's most burdensome diseases," said Prof. Wolfgang Grisold, the WFN's Secretary-General. "Driving awareness will help the scientific community to more effectively advocate on behalf of this vast population of patients in need."

Migraine is a disabling neurological disease. It is characterised by severe head pain, cognitive impairment, nausea, vomiting, dizziness, vertigo, and sensitivity to light, sound, and touch. It is also highly associated with other diseases such as stroke, heart disease, epilepsy, depression, chronic pain, among others. In order to help patients find relief and improve their quality of life, early diagnosis and access to effective treatment are vital.

"Providing patients with appropriate, evidence-based care would dramatically move the needle on the global burden of migraine," says Wijeratne. "There is a need for improved standards of care so that all can access safe treatment regardless of financial situation, gender, culture or location."

The Painful Truth About Migraine

The key to driving improvements in migraine care is spreading awareness. This year, World Brain Day is taking to social media to ask people all over the world to share their Painful Truth about migraine using the hashtags #worldbrainday and #thepainfultruth.

Throughout June and July, we are asking patients from around the world to share 'The Painful Truth' about migraine on social media. By encouraging people to speak up, we hope to elevate the patient voice and bring visibility to an invisible illness.

Patients, health care professionals, advocates and caregivers are all encouraged to also attend the World Brain Day webinar that will take place on in July to share more information about migraine. During the 60-minute presentation, key migraine experts from around the world will offer vital insights on the disease, as well as outline a strategy to raise the bar on patient care regardless of age, gender, culture or location.

Partnering to Influence Change

To help ensure that this is one of the most impactful World Brain Days to date, WFN is partnering with national neurology associations, leading migraine and headache organisations around the world to share the message.

"The concerted actions of professionals and patient advocacy will help in providing the best therapies available to the many," says International Headache Society President Lars Edvinsson. "There is a new class of effective and specific prophylactic medications directed toward the CGRP system that are already on the market and showing good responses. With further novel specific therapies on the way, the time to make a difference is right now."

Additionally, World Brain Day will be broadly promoted alongside the American Migraine Foundation (AMF) in a prominent ad displayed in New York's Times Square during Migraine and Headache Awareness Month in June.

"Nearly 380,000 pedestrians enter Times Square daily, hailing from all corners of the world," said David Dodick, MD, Professor of Neurology at Mayo Clinic, Chair of the American Migraine Foundation and Immediate Past-President of the International Headache Society. "There is no better place to spread the word about a disease that knows no borders than one of the world's most international locations."

The annual World Brain Day takes place on July 22 and is devoted to a different topic each year. The choice of date was no coincidence: the WFN was founded on July 22, 1957. It's only fitting that WFN recognises its 62nd year of action by focusing its efforts on fighting a problem as pervasive and debilitating as migraine.

"It's imperative that the world understands the physical pain and societal impact of migraine," said WFN President Prof. William Carroll. "The World Federation of Neurology stands beside the more than one billion people living with migraine."

Guidelines for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition, is now published in Cephalalgia and freely available